Clearance of HCV by combination therapy of pegylated interferon α-2a and ribavirin improves insulin resistance

Gut and Liver

Volumn 3, Issue 2, 2009, Pages 108-115

  Hong, Joo Kim ^a   Jung, Ho Park ^a   Dong, Il Park ^a   Yong, Kyun Cho ^a   Chong, Il Sohn ^a   Woo, Kyu Jeon ^a   Byung, Ik Kim ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Antiviral treatment; Chronic hepatitis C; Homeostasis model assessment; Insulin resistance; Pegylated interferon

Indexed keywords

GLUCOSE; INSULIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; TREATMENT RESPONSE; VIRUS LOAD;

EID: 67649249726     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2009.3.2.108     Document Type: Article

References (24)

1. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994;21:1135-1139.
2. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-333. (Pubitemid 29088433)
3. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003;125:1695-1704. (Pubitemid 37500434)
4. Adami HO, Chow WH, Nyrén O, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996;88:1472-1477. (Pubitemid 26340049)
5. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-468. (Pubitemid 38182303)
6. Nagao Y, Kawaguchi T, Tanaka K, Kumashiro R, Sata M. Extrahepatic manifestations and insulin resistance in an HCV hyperendemic area. Int J Mol Med 2005;16:291-296.
7. Sumie S, Kawaguchi T, Komuta M, et al. Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. Oncol Rep 2007;18:545-552.
8. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006;43:1168. (Pubitemid 43724645)
9. Sanyal AJ, Chand N, Comar K, Mirshahi F. Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic fatty liver disease. Hepatology 2004;40:179A.
10. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to pe ginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641. (Pubitemid 40585366)
11. Konrad T, Zeuzem S, Vicini P, et al. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest 2000;30:111-121. (Pubitemid 30079568)
12. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007;102:570-576. (Pubitemid 46328143)
13. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-2399. (Pubitemid 23332300)
14. Chiles R, Tzagournis M. Excessive serum insulin response to oral glucose in obesity and mild diabetes. Study of 501 patients. Diabetes 1970;19:458-464.
15. Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep 2004;4:194-198. (Pubitemid 38899149)
16. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848. (Pubitemid 38298332)
17. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-1508. (Pubitemid 39435150)
18. Kawaguchi T, Nagao Y, Tanaka K, et al. Causal relationship between hepatitis C virus core and the development of type 2 diabetes mellitus in a hepatitis C virus hyperendemic area: a pilot study. Int J Mol Med 2005;16:109-114.
19. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989;38:641-647. (Pubitemid 19125614)
20. Imano E, Kanda T, Ishigami Y, et al. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol 1998;28:189-193. (Pubitemid 28116425)
21. Ito Y, Takeda N, Ishimori M, Akai A, Miura K, Yasuda K. Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C. J Hepatol 1999;31:215-220. (Pubitemid 29349745)
22. Tai TY, Lu JY, Chen CL, et al. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003;178:457-465. (Pubitemid 37220172)
23. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134:416-423. (Pubitemid 351181308)
24. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 2003;125:1695-1704. (Pubitemid 37500434)